Letrobol 2.5 mg

Letrobol 2.5 mg contains the non-steroidal aromatase inhibitor letrozole. In clinical medicine, it is approved for treatment of hormone receptor-positive breast cancer in postmenopausal women. In non-medical bodybuilding contexts, it is commonly referenced for gynecomastia reversal and managing estrogenic side effects from aromatizing anabolic steroids, though such use falls outside approved indications.

The standard clinical dose is 2.5 mg taken once daily for breast cancer treatment. In non-medical contexts, letrozole is commonly referenced at lower doses of 0.25–1.25 mg every other day or twice weekly, with gyno reversal protocols using 1.25–2.5 mg daily for 10–14 days. These non-medical practices are not derived from controlled clinical trials.

Letrozole is an aromatase inhibitor, not an anabolic steroid, and does not suppress endogenous testosterone production. Post-cycle therapy is not applicable to letrozole in the context of hormonal recovery. In non-medical settings, PCT protocols typically involve Clomiphene or Tamoxifen rather than letrozole. Tapering letrozole after daily use is recommended to avoid estrogen rebound.

Letrozole competitively binds to the heme of the cytochrome P450 subunit of the aromatase enzyme, blocking the conversion of androgens to estrogens. This results in a reduction of estrogen biosynthesis in all tissues. Daily doses of 0.1 mg to 5 mg suppress plasma concentrations of estradiol, estrone, and estrone sulfate by 75% to 95% from baseline.

Maximal estrogen suppression with letrozole is achieved within two to three days of starting treatment. A single 2.5 mg dose can produce a 46% reduction in estradiol in eugonadal men. This rapid onset is why letrozole is considered a last-resort AI and why dose reduction should be implemented immediately if crashed-estrogen symptoms appear.

There is no universally established "best" aromatase inhibitor, and each has distinct characteristics. Letrozole is the most potent AI available, achieving greater than 98% whole-body aromatase inhibition at oncology doses. However, its potency makes it prone to over-suppression, and experienced users recommend reserving it for gyno reversal or cases where weaker AIs have failed.

Letrobol and Anastrozole are both non-steroidal aromatase inhibitors but differ in potency. Letrozole is significantly more potent and achieves more complete estrogen suppression, while anastrozole has a more manageable profile for routine use. Experienced users often recommend anastrozole as a first-line AI and letrozole only for gyno rescue.

Letrobol and Exemestane have different mechanisms. Letrozole is a non-steroidal competitive inhibitor, while exemestane is a steroidal irreversible (suicide) inhibitor. Exemestane's effects persist until new enzyme is synthesized, while letrozole's reversible binding means effects diminish as drug concentrations decline. Letrozole is more potent at suppressing estrogen.

Letrobol 2.5 mg is labeled at 2.5 mg of letrozole per tablet. This is the standard clinical dose for breast cancer treatment. In non-medical bodybuilding contexts, 2.5 mg is considered a high dose for routine estrogen management, and lower doses or less frequent administration are commonly referenced to avoid crashing estrogen levels.

Letrobol 2.5 mg is labeled at 2.5 mg of letrozole per tablet. It is supplied as oral tablets in packs of 50 or 100 tablets manufactured by British Dragon.

Yes. A published laboratory report dated March 23, 2026 measured Letrobol 2.5 mg at 2.52 mg, equivalent to 100.80% of its 2.5 mg label claim. The complete report can be viewed in the Lab Reports tab.